Key result
Tafamidis administration resulted in no significant deterioration of representative echocardiographic parameters, including left ventricular ejection fraction, in patients with transthyretin amyloid cardiomyopathy over a mean follow-up of 16 months.
Why the study?
Echocardiographic details of the association of tafamidis with cardiac morphology remain undetermined, and whether efficacy varies by the degree of cardiac involvement is unknown.
Does tafamidis prevent worsening of echocardiographic parameters in patients with transthyretin amyloid cardiomyopathy?
Observational (n=41)
No
Does tafamidis prevent worsening of echocardiographic parameters in patients with transthyretin amyloid cardiomyopathy?
Answers are grounded in this paper and cite their sources.
Tafamidis effects on ATTR-CM morphology require prospective confirmation; leaves open variation by cardiac involvement severity.
BACKGROUND: The efficacy of a therapy for patients with transthyretin amyloid cardiomyopathy (ATTR-CM) has not been proven, but tafamidis has been associated with favorable outcomes. However, echocardiographic details of the association of tafamidis with cardiac morphology remain undetermined. Moreover, whether the efficacy of tafamidis varies with the degree of cardiac involvement remains unknown. Using echocardiography, this study investigated the impact of tafamidis on the cardiac morphology of patients with ATTR-CM. METHODS AND RESULTS: ; New York Heart Association Class I-II vs. Class III; age ≥80 vs. <80 years). CONCLUSIONS: Tafamidis may prevent worsening of various representative echocardiographic parameters of patients with ATTR-CM. This effect is also seen in patients with relatively advanced disease and in those who are elderly.
No takes yet. Share an insight, caveat, or question.
Ichikawa et al. (2023) conducted an observational in Transthyretin amyloid cardiomyopathy (ATTR-CM) (n=41). Tafamidis vs. Baseline (pre-administration) was evaluated on Left ventricular ejection fraction (LVEF) (p=0.638). Tafamidis administration resulted in no significant deterioration of representative echocardiographic parameters, including left ventricular ejection fraction, in patients with transthyretin amyloid cardiomyopathy over a mean follow-up of 16 months.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: